NDC product
TICE BCG
NDC 0052-0602 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0052-0602 |
|---|---|
| Proprietary name | TICE BCG |
| Nonproprietary name | BACILLUS CALMETTE-GUERIN |
| Substances | BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN |
| Dosage form | POWDER, FOR SUSPENSION |
| Route | INTRAVESICAL |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA102821 |
| Pharmacologic classes | Actively Acquired Immunity [PE], BCG Vaccine [CS], Increased Immunologically Active Molecule Activity [PE], Increased Macrophage Proliferation [PE], Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC], Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] and 2 more |
| Marketing start | Aug 24, 1990 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: